LDL cholesterol
Coverage of LDL cholesterol in the Nexus archive.
- FDA approves new kind of cholesterol pill
The FDA has approved the first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol. This new cholesterol pill represents a novel treatment option for managing elevated cholesterol levels.
- A new pill could help millions of people lower their cholesterol
The FDA has approved a pill form of a powerful medication that targets bad LDL cholesterol. Dr. Jon LaPook highlights this development as a potential aid for millions to lower their cholesterol.
- FDA nod to Merck’s cholesterol pill opens a new frontier in cardiovascular care
The FDA approved Merck’s Lipfendra, the first non-injectable pill targeting PCSK9 to significantly reduce LDL cholesterol in patients not adequately controlled by statins. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under the FDA's fast-track program.
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
The FDA approved Merck's Lipfendra, the first non-injectable pill to block PCSK9 and significantly reduce LDL cholesterol in high-risk patients. Clinical trials showed over 55% LDL reduction in six months, with minimal side effects, positioning it as an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
The FDA approved Merck's Lipfendra, the first non-injectable pill to significantly reduce LDL cholesterol in high-risk patients by blocking the PCSK9 protein. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under an accelerated FDA program led by Dr. Marty Makary. It offers an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.
- Merck won FDA approval for the first cholesterol pill to rival powerful injectables
Merck received FDA approval for Lipfendra, a once-daily cholesterol pill that reduced LDL cholesterol by up to 59% in late-stage trials, making it a competitor to existing injectable treatments.
- ‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose
A new treatment has been developed that can reduce bad LDL cholesterol levels by up to 62% with a single dose, potentially lowering the risk of plaque buildup in blood vessels and heart-related complications.
- One-and-done injection can slash 'bad' cholesterol by 60 per cent, according to new study
A one-time injection has been shown to reduce 'bad' cholesterol levels by 60% in a new study, offering a potential breakthrough in managing high cholesterol.
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly's gene therapy reduced cholesterol by 62% in a Phase 1 trial, with no serious adverse events. The company acquired the therapy through its $1 billion buyout of Verve Therapeutics and plans Phase 2 trials. Lilly also agreed to buy three vaccine developers (Curevo, LimmaTech Biologics, and Vaccine Company) in deals totaling up to $4 billion, expanding its focus on infectious diseases.
- STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly reported a 62% reduction in LDL cholesterol levels in a Phase 1 trial using its gene-editing therapy, VERV-102, acquired from Verve Therapeutics. The therapy showed no serious adverse events, marking a significant safety improvement over Verve's previous shelved candidate. The treatment is positioned as a potential one-time solution for preventing heart disease.
- New treatment cuts bad cholesterol by nearly 50% without statins
Researchers have developed DNA-based molecules that block the PCSK9 protein, reducing LDL cholesterol levels by nearly 50% and offering a statin-free alternative for treating high cholesterol and heart disease.